@article {Buchegger896, author = {Franz Buchegger and Cristian Antonescu and Claudine Helg and Marek Kosinski and John O. Prior and Angelika Bischof Delaloye and Oliver W. Press and Nicolas Ketterer}, title = {Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission}, volume = {52}, number = {6}, pages = {896--900}, year = {2011}, doi = {10.2967/jnumed.111.087460}, publisher = {Society of Nuclear Medicine}, abstract = {The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma. Methods: More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refractory lymphoma patients with a single administration of nonmyeloablative therapy with tositumomab and 131I-tositumomab. The 16 patients had a mean of 3.1 (range, 1{\textendash}6) previous chemotherapy and antibody treatments. Results: Six of 12 relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6{\textendash}10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after radioimmunotherapy, and 1 patient had a partial response of 10 mo. Conclusion: Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50\%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/52/6/896}, eprint = {https://jnm.snmjournals.org/content/52/6/896.full.pdf}, journal = {Journal of Nuclear Medicine} }